Selected research
Industry Research
Genetic Engineering Drug Industry Research Report 2026
Market perspective
The global Genetic Engineering Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Genetic Engineering Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Genetic Engineering Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Genetic Engineering Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Genetic Engineering Drug include Tonghua Dongbao Pharmaceutical, Shenzhen Neptunus Interlong Bio-Technique, Shanghai Lansheng Guojian Pharmaceutical, Jiangsu Sihuan Bioengineering, Anhui Anke Biotechnology, GeneScience Pharmaceuticals, Biotech Pharmaceutical, Beijing SL Pharmaceutical and 3SBio, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Genetic Engineering Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Genetic Engineering Drug Market by Company
Tonghua Dongbao Pharmaceutical
Shenzhen Neptunus Interlong Bio-Technique
Shanghai Lansheng Guojian Pharmaceutical
Jiangsu Sihuan Bioengineering
Anhui Anke Biotechnology
GeneScience Pharmaceuticals
Biotech Pharmaceutical
Beijing SL Pharmaceutical
3SBio
Genetic Engineering Drug Segment by Type
Recombinant Human Insulin
Recombinant Human Growth Hormone
Recombinant Human Interferon
Recombinant Human Erythropoietin
Monoclonal Antibody
Genetic Engineering Drug Segment by Application
Medicine
Research
Agriculture
Industrial
Other
Genetic Engineering Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Genetic Engineering Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Genetic Engineering Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Genetic Engineering Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Genetic Engineering Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Genetic Engineering Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Genetic Engineering Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Recombinant Human Insulin
- Recombinant Human Growth Hormone
- Recombinant Human Interferon
- Recombinant Human Erythropoietin
- Monoclonal Antibody
Applications
- Medicine
- Research
- Agriculture
- Industrial
- Other
Companies covered
- Tonghua Dongbao Pharmaceutical
- Shenzhen Neptunus Interlong Bio-Technique
- Shanghai Lansheng Guojian Pharmaceutical
- Jiangsu Sihuan Bioengineering
- Anhui Anke Biotechnology
- GeneScience Pharmaceuticals
- Biotech Pharmaceutical
- Beijing SL Pharmaceutical
- 3SBio
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Genetic Engineering Drug Market Size (2021-2032)
- 2.2.2 Global Genetic Engineering Drug Sales (2021-2032)
- 2.2.3 Global Genetic Engineering Drug Market Average Price (2021-2032)
- 2.3 Genetic Engineering Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Recombinant Human Insulin
- 2.3.3 Recombinant Human Growth Hormone
- 2.3.4 Recombinant Human Interferon
- 2.3.5 Recombinant Human Erythropoietin
- 2.3.6 Monoclonal Antibody
- 2.4 Genetic Engineering Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Medicine
- 2.4.3 Research
- 2.4.4 Agriculture
- 2.4.5 Industrial
- 2.4.6 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Genetic Engineering Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Genetic Engineering Drug Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Genetic Engineering Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Genetic Engineering Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Genetic Engineering Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Genetic Engineering Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Genetic Engineering Drug, Product Type & Application
- 3.8 Global Manufacturers of Genetic Engineering Drug, Established Date
- 3.9 Global Genetic Engineering Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Tonghua Dongbao Pharmaceutical
- 4.1.1 Tonghua Dongbao Pharmaceutical Company Information
- 4.1.2 Tonghua Dongbao Pharmaceutical Business Overview
- 4.1.3 Tonghua Dongbao Pharmaceutical Genetic Engineering Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Tonghua Dongbao Pharmaceutical Genetic Engineering Drug Product Portfolio
- 4.1.5 Tonghua Dongbao Pharmaceutical Recent Developments
- 4.2 Shenzhen Neptunus Interlong Bio-Technique
- 4.2.1 Shenzhen Neptunus Interlong Bio-Technique Company Information
- 4.2.2 Shenzhen Neptunus Interlong Bio-Technique Business Overview
- 4.2.3 Shenzhen Neptunus Interlong Bio-Technique Genetic Engineering Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Shenzhen Neptunus Interlong Bio-Technique Genetic Engineering Drug Product Portfolio
- 4.2.5 Shenzhen Neptunus Interlong Bio-Technique Recent Developments
- 4.3 Shanghai Lansheng Guojian Pharmaceutical
- 4.3.1 Shanghai Lansheng Guojian Pharmaceutical Company Information
- 4.3.2 Shanghai Lansheng Guojian Pharmaceutical Business Overview
- 4.3.3 Shanghai Lansheng Guojian Pharmaceutical Genetic Engineering Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Shanghai Lansheng Guojian Pharmaceutical Genetic Engineering Drug Product Portfolio
- 4.3.5 Shanghai Lansheng Guojian Pharmaceutical Recent Developments
- 4.4 Jiangsu Sihuan Bioengineering
- 4.4.1 Jiangsu Sihuan Bioengineering Company Information
- 4.4.2 Jiangsu Sihuan Bioengineering Business Overview
- 4.4.3 Jiangsu Sihuan Bioengineering Genetic Engineering Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Jiangsu Sihuan Bioengineering Genetic Engineering Drug Product Portfolio
- 4.4.5 Jiangsu Sihuan Bioengineering Recent Developments
- 4.5 Anhui Anke Biotechnology
- 4.5.1 Anhui Anke Biotechnology Company Information
- 4.5.2 Anhui Anke Biotechnology Business Overview
- 4.5.3 Anhui Anke Biotechnology Genetic Engineering Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Anhui Anke Biotechnology Genetic Engineering Drug Product Portfolio
- 4.5.5 Anhui Anke Biotechnology Recent Developments
- 4.6 GeneScience Pharmaceuticals
- 4.6.1 GeneScience Pharmaceuticals Company Information
- 4.6.2 GeneScience Pharmaceuticals Business Overview
- 4.6.3 GeneScience Pharmaceuticals Genetic Engineering Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 GeneScience Pharmaceuticals Genetic Engineering Drug Product Portfolio
- 4.6.5 GeneScience Pharmaceuticals Recent Developments
- 4.7 Biotech Pharmaceutical
- 4.7.1 Biotech Pharmaceutical Company Information
- 4.7.2 Biotech Pharmaceutical Business Overview
- 4.7.3 Biotech Pharmaceutical Genetic Engineering Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Biotech Pharmaceutical Genetic Engineering Drug Product Portfolio
- 4.7.5 Biotech Pharmaceutical Recent Developments
- 4.8 Beijing SL Pharmaceutical
- 4.8.1 Beijing SL Pharmaceutical Company Information
- 4.8.2 Beijing SL Pharmaceutical Business Overview
- 4.8.3 Beijing SL Pharmaceutical Genetic Engineering Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Beijing SL Pharmaceutical Genetic Engineering Drug Product Portfolio
- 4.8.5 Beijing SL Pharmaceutical Recent Developments
- 4.9 3SBio
- 4.9.1 3SBio Company Information
- 4.9.2 3SBio Business Overview
- 4.9.3 3SBio Genetic Engineering Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 3SBio Genetic Engineering Drug Product Portfolio
- 4.9.5 3SBio Recent Developments
5 Global Genetic Engineering Drug Market Scenario by Region
- 5.1 Global Genetic Engineering Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Genetic Engineering Drug Sales by Region: 2021-2032
- 5.2.1 Global Genetic Engineering Drug Sales by Region: 2021-2026
- 5.2.2 Global Genetic Engineering Drug Sales by Region: 2027-2032
- 5.3 Global Genetic Engineering Drug Revenue by Region: 2021-2032
- 5.3.1 Global Genetic Engineering Drug Revenue by Region: 2021-2026
- 5.3.2 Global Genetic Engineering Drug Revenue by Region: 2027-2032
- 5.4 North America Genetic Engineering Drug Market Facts & Figures by Country
- 5.4.1 North America Genetic Engineering Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Genetic Engineering Drug Sales by Country (2021-2032)
- 5.4.3 North America Genetic Engineering Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Genetic Engineering Drug Market Facts & Figures by Country
- 5.5.1 Europe Genetic Engineering Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Genetic Engineering Drug Sales by Country (2021-2032)
- 5.5.3 Europe Genetic Engineering Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Genetic Engineering Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Genetic Engineering Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Genetic Engineering Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Genetic Engineering Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Genetic Engineering Drug Market Facts & Figures by Country
- 5.7.1 South America Genetic Engineering Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Genetic Engineering Drug Sales by Country (2021-2032)
- 5.7.3 South America Genetic Engineering Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Genetic Engineering Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Genetic Engineering Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Genetic Engineering Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Genetic Engineering Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Genetic Engineering Drug Sales by Type (2021-2032)
- 6.1.1 Global Genetic Engineering Drug Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Genetic Engineering Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Genetic Engineering Drug Revenue by Type (2021-2032)
- 6.2.1 Global Genetic Engineering Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Genetic Engineering Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Genetic Engineering Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Genetic Engineering Drug Sales by Application (2021-2032)
- 7.1.1 Global Genetic Engineering Drug Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Genetic Engineering Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Genetic Engineering Drug Revenue by Application (2021-2032)
- 7.2.1 Global Genetic Engineering Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Genetic Engineering Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Genetic Engineering Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Genetic Engineering Drug Value Chain Analysis
- 8.1.1 Genetic Engineering Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Genetic Engineering Drug Production Mode & Process
- 8.2 Genetic Engineering Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Genetic Engineering Drug Distributors
- 8.2.3 Genetic Engineering Drug Customers
9 Global Genetic Engineering Drug Analyzing Market Dynamics
- 9.1 Genetic Engineering Drug Industry Trends
- 9.2 Genetic Engineering Drug Industry Drivers
- 9.3 Genetic Engineering Drug Industry Opportunities and Challenges
- 9.4 Genetic Engineering Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst